Myrio Therapeutics Pty Ltd
- Biotech or pharma, therapeutic R&D
Myrio Tx is pioneering a new frontier in solid tumor immuno-oncology with its T cell engager platform designed to target intracellular antigens presented on the cell surface via peptide-MHC (pHLA) complexes. Our approach integrates advanced T cell engager-based technologies, including engineered bispecific antibody molecules and antibody constructs for cell therapy (e.g., CAR-T), to deliver highly specific and potent immune responses against tumors. Our lead candidate has an approved IND and is poised to recruit for a first-in-human (FIH) Phase 1 trial (NCT07007117). We are advancing a robust pipeline of 17 candidates across 11 high-value solid tumor targets.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}